Table 6.
Antiviral activity of thiourea derivatives against ssRNA-(RSV, VSV), dsRNA (Reo-1) and dsDNA (VV, HSV-1) viruses and cytotoxicity against the cell lines used in the assays.
| Compounds | BHK a CC50 | Reo-1 b EC50 | Vero-76 c CC50 | RSV d EC50 | VSV e EC50 | VV f EC50 | HSV-1 g EC50 |
|---|---|---|---|---|---|---|---|
| 1 | 48 | >48 | 64 | >64 | >64 | >64 | >64 |
| 2 | 44 | >44 | 56 | >56 | >56 | >56 | >56 |
| 3 | 16 | >16 | 75 | 20 ± 3.0 | >75 | >75 | >75 |
| 4 | 47 | >47 | 55 | >55 | >55 | >55 | >55 |
| 5 | 34 | >34 | 29 | >29 | >29 | >29 | >29 |
| 6 | 10 | >10 | 13 | >13 | >13 | >13 | >13 |
| 7 | 10 | >10 | 12 | >12 | >12 | >12 | >12 |
| 8 | 10 | >10 | 13 | >13 | >13 | >13 | >13 |
| 9 | 13 | >13 | 14 | >14 | >14 | >14 | >14 |
| 10 | 52 | >52 | >100 | >100 | >100 | >100 | >100 |
| 11 | 34 | >34 | 73 | >73 | >73 | >73 | >73 |
| 12 | 16 | >16 | 60 | >60 | >60 | >60 | >60 |
| 13 | 11 | >11 | 53 | >53 | >53 | >53 | >53 |
| 14 | 6.0 | >6.0 | 32 | >32 | >32 | >32 | >32 |
| 15 | 28 | >28 | 46 | 20 ± 2.5 | >46 | >46 | >46 |
| 16 | 18 | >18 | >100 | 30 ± 2.6 | >100 | >100 | >100 |
| 17 | 30 | >30 | 53 | >53 | >53 | >53 | >53 |
| 18 | >100 | 61 | >100 | >100 | >100 | >100 | >100 |
| 19 | 35 | >35 | 89 | >89 | >89 | >89 | >89 |
| 20 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 21 | 11 | >11 | 11 | >11 | >11 | >11 | >11 |
| 22 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 23 | 10 | >10 | 17 | >17 | >17 | >17 | >17 |
| 24 | 9.0 | >9.0 | 16 | >16 | >16 | >16 | >16 |
| 25 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 26 | 12 | >12 | 17 | >17 | >17 | >17 | >17 |
| 27 | 9.5 | >9.5 | 12 | >12 | >12 | >12 | >12 |
| 28 | 30 | >30 | 32 | >32 | >32 | >32 | >32 |
| 2′-C-methyl-cytidine | >100 | 10 ± 1.2 | |||||
| 6-Aza-uridine | 12 | 1.4 ± 0.06 | |||||
| Mycophenolic acid | 13 | 1.5 ± 0.2 | |||||
| Acycloguanosine | >100 | 3.0 ± 0.2 | |||||
Data represent mean values for three independent determinations. Standard deviations are reported for the more active compounds. Also for the others values the variation was less than 15%. a Compound concentration (µM) required to reduce the proliferation of mock-infected BHK cells by 50%. b Compound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced cytopathogenicity. c Compound concentration (µM) required to reduce the viability of mock-infected VERO-76 cells by 50%. d–g Compound concentration (µM) required to reduce the plaque number of RSV d, VSV e, VV f, HSV-1 g by 50% in VERO-76 monolayers.